LSI Segment Divestment

Market Small Molecules Lonza Operations Growth driven by: Oncology (with a focus on Highly Potent API) Specialized medicines (with US and Europe showing high demand) Trend for small companies owning majority of clinical pipeline continues - with high propensity to outsource Speed to market is a focus as more than half of new market approvals are on an accelerated pathway COVID-19 impacts have been managed with supply chain planning and virtual customer engagement New project acquisition supported by high brand equity and strong contracting trends New service offerings launched in 2020 include Solid Form Services and Inhalation New growth investments approved to support customers in early phase development and to manage high capacity utilization in existing assets Financial Performance1 High single-digit sales growth across 2020 Margin growth resulting from leveraged performance and sales growth Double-digit sales growth forecast expected in 2021 from new customer contracts 1 Comparison versus 2019 at a constant exchange rate (CER) 23

View entire presentation